Phase II failures: 2008–2010
The DOI matches its Crossref record.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the decreasing success rate of drugs entering clinical trials (29) suggests that the pharmacology of target-based drug candidates predicts their therapeutic efficacy and toxicity poorly.”
From Cytokine Response Is Determined by Duration of Receptor and Signal Transducers and Activators of Transcription 3 (STAT3) Activation (2013) · cites this paper as [29]
In the citing paper
“In the development of pharmaceutical drugs over 80% fail to reach ‘Phase III’ effectiveness trials, even after considerable investment [4].”
From Exploratory studies to decide whether and how to proceed with full-scale evaluations of public health interventions: a systematic review of guidance (2018) · cites this paper as [4]
Citations
Cites
Still being checked.
Cited by
Items 501–600 of 624
Anti-Infective Polypeptides for Combating Bacterial and Viral Infections
(2014) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781608058549114010003 · Cited by 2
Translational Pharmacology: New approach of drug discovery
Bharati, D., Dhokchawle, B. V., Tauro, S. J., & Rawat, S. S. (2014) · International Journal of Research in Pharmacology & Pharmacotherapeutics · doi:10.61096/ijrpp.v3.iss2.2014.130-135 · Cited by 1
Neuroimaging in Psychiatric Drug Development and Radioligand Development for New Targets
Takano, A., Halldin, C., & Farde, L. (2014) · Springer eBooks · doi:10.1007/978-3-642-40384-2_1 · Cited by 3
Impact of Microdose Clinical Trials in the Preclinical Stage
Kim, S. (2014) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.13-00248-1 · Cited by 1
Pharmacodynamics biomarkers: application and considerations in clinical development
Mito, S., Sakai, M., & Suzuki, M. (2016) · Folia Pharmacologica Japonica · doi:10.1254/fpj.148.302 · Cited by 1
Webb, C. R., & Grisham, M. B. (2017) · Springer eBooks · doi:10.1007/978-3-319-33703-6_15 · Cited by 1
The State of Science and Unreliable Research
Hughes, L. D. (2014) · Cited by 1
Development of Novel Radiopharmaceuticals: Problems, Decisions and More Problems
Babich, J. W., & Haberkorn, U. (2020) · SpringerBriefs in ethics · doi:10.1007/978-3-030-61412-6_6 · Cited by 1
Howard, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-93224-8_30 · Cited by 1
Alternative Animal Models in Cancer Research
Meenu, M. S., Soumya, V. S., Mathew, J. M., & Panicker, S. P. (2022) · Handbook of Animal Models and its Uses in Cancer Research · doi:10.1007/978-981-19-1282-5_55-1 · Cited by 1
Negative findings but positive contributions in cardiovascular research
Chen, K., & Zeng, C. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121494 · Cited by 1
Hori, S., Taniguchi, H., Yoshimura, S., Takeda, K., Yamashita, R., Kimishima, A., & Harada, K. (2024) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c24-00050 · Cited by 1
The Roles of Endogenous Opioids in Placebo and Nocebo Effects: From Pain to Performance to Prozac
Kerr, P. L., & Gregg, J. M. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-45493-6_10 · Cited by 1
Advanced Strategy and Future Perspectives in Drug Delivery System
Umamaheswari, A., Puratchikody, A., Prabu, S. L., & Thirumurugan, R. (2025) · Pharmaceutical science. · doi:10.5772/intechopen.1008498 · Cited by 2
A pan-cancer, pan-treatment model for predicting drug responses from patient-derived xenografts
Gupta, S., Mohani, V. K., Ghislat, G., Ballester, P. J., & Ahmad, S. (2025) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqaf111 · Cited by 1
Saitoh, R., Nagayasu, M., Shibahara, N., Ono, N., Suda, A., Kato, M., & Ishigai, M. (2013) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-13-rg-066 · Cited by 1
Do We Need a Science of Science?
Maiväli, Ü. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-418689-7.00001-6 · Cited by 1
Computational approaches to drug target identification
Freeman, T. B., & Lum, P. Y. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9780511989421.003 · Cited by 1
Figueiredo, A. C. D. M. (2017) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2017.10.003 · Cited by 1
Zhang, P. G. Y., Carroll, K., Hobart, M., Augustine, C., & Koch, G. G. (2017) · Pharmaceutical Statistics · doi:10.1002/pst.1839 · Cited by 1
Movia, D., & Prina‐Mello, A. (2018) · InTech eBooks · doi:10.5772/intechopen.69447 · Cited by 2
Preclinical Organotypic Models for the Assessment of Novel Cancer Therapeutics and Treatment
Ward, C., Meehan, J., Gray, M., Kunkler, I. H., Langdon, S. P., Murray, A., & Argyle, D. J. (2019) · Current topics in microbiology and immunology · doi:10.1007/82_2019_159 · Cited by 2
The Impact of Chemical Biology on Drug Discovery
Plettenburg, O. (2019) · Israel Journal of Chemistry · doi:10.1002/ijch.201900007 · Cited by 1
Next generation zebrafish-based drug discovery and precision medicine
Tanaka, T., & Koiwa, J. (2019) · Folia Pharmacologica Japonica · doi:10.1254/fpj.154.78 · Cited by 1
Oyewole, A. L., Oyafemi, K. O., Badmus, K. S., Omoleye, J. O., Abubakar, M. F., Adeniyi-Raheem, O., Amedu, A.-H., Lawal, D. L., Ijiyode, A. O., Yussuf, A. O., et al. (2020) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2020.108890 · Cited by 2
Pharmacological Target Engagement and Validation
Kenakin, T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00029-3 · Cited by 1
Early Development of Erenumab for Migraine Prophylaxis
Vargas, G. A. (2021) · Springer eBooks · doi:10.1007/978-3-030-62351-7_17 · Cited by 1
COVID-19 Drug Development: Role of Drug Repurposing
David, K. B., Azeez, Y. O., & Okafor, C. C. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.107939 · Cited by 1
Alternative Animal Models in Cancer Research
Meenu, M. S., Soumya, V. S., Mathew, J. M., & Panicker, S. P. (2023) · Handbook of Animal Models and its Uses in Cancer Research · doi:10.1007/978-981-19-3824-5_55 · Cited by 1
Plágio e condutas inadequadas em pesquisa: onde chegamos e o que podemos fazer
Chamon, W. (2013) · Arquivos Brasileiros de Oftalmologia · doi:10.1590/s0004-27492013000600001 · Cited by 1
MARKERS OF BONE TURNOVER IN PRECLINICAL DEVELOPMENT OF DRUGS FOR SKELETAL DISEASES
Rissanen, J. P. (2013) · UTUPub (University of Turku) · Cited by 4
Recent Applications of Web Semantics in eLifeScience
Clark, T., & Roos, M. (2014) · Journal of Web Semantics · doi:10.1016/j.websem.2014.11.005 · Cited by 1
Kartal-Hodzic, A. (2012) · Työväentutkimus Vuosikirja · Cited by 1
Compound Attrition at the Preclinical Phase
Hop, C. E. C. A. (2015) · Wiley eBooks · doi:10.1002/9781118819586.ch2 · Cited by 3
Lead Generation for Challenging Targets
Wan, J., Dou, D., Song, H., Cheng, X. W. X., & Li, J. (2016) · Methods and principles in medicinal chemistry · doi:10.1002/9783527677047.ch10 · Cited by 1
Bell, A., Fecke, W., & Williams, C. (2015) · Wiley eBooks · doi:10.1002/9781118819586.ch9 · Cited by 1
The Transgenic Diabetic Pig Heart
Ishikawa, K. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.018 · Cited by 1
Why Do Promising Therapies Stall in Development and How Can We Move Them Forward?
Wegner, C. D., Goodwin, A., Cook, J. C., Allamneni, K. P., Sohn, J., & McVean, M. (2017) · International Journal of Toxicology · doi:10.1177/1091581817709773 · Cited by 1
Pharmacokinetics and Pharmacodynamics of Antisense Oligonucleotides
Lightfoot, H. L., Schneider, A., & Hall, J. (2018) · Wiley eBooks · doi:10.1002/9781119070153.ch4 · Cited by 4
Yamazaki, S. (2018) · Methods and principles in medicinal chemistry · doi:10.1002/9783527801756.ch16 · Cited by 1
Animal Models in Science and Research
Greek, R. (2019) · Wiley eBooks · doi:10.1002/9781118907283.ch29 · Cited by 1
Clinical Validation and Biomarker Translation
Kim, J. V., Ng, R. T., Balshaw, R. F., Keown, P. A., McMaster, R., McManus, B. M., Lam, K., & Tebbutt, S. J. (2020) · doi:10.1002/9781119187547.ch17 · Cited by 1
Prédiction des constantes cinétiques de complexes protéine-ligand
Ziada, S. (2019) · theses.fr (ABES) · doi:10.70675/1d581f29z4cb3z4657z941ezb57faa759067 · Cited by 1
INTEGRATION OF DISCOVERY AND DEVELOPMENT
Ho, R. J. Y., & Gibaldi, M. (2013) · doi:10.1002/9781118660485.ch19
Hunter, J. A. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04239.x
Systems Pharmacology and Pharmacogenomics for Drug Discovery and Development
Talwar, P., Silla, Y., Grover, S., Gupta, M., Grewal, G. K., & Kukreti, R. (2014) · Springer eBooks · doi:10.1007/978-94-017-9514-2_9
Gastambide, F., & Gilmour, G. (2012) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.63
Development of a cell self-assembled 3-dimensional in vitro skeletal muscle tissue model
Forte, J. M., Fidanza, A. M., & Page, R. L. (2014) · IEEE Annual Northeast Bioengineering Conference (NEBEC) · doi:10.1109/nebec.2014.6972790
Disease Modeling and Drug Discovery Using Human Pluripotent Stem Cells
Honoré, C., & Hansson, M. D. (2013) · Stem cell biology and regenerative medicine · doi:10.1007/978-1-4614-8066-2_15
Translational Concept and Determination of Drug Absorption
Yanni, S. B. (2015) · Wiley eBooks · doi:10.1002/9781118838440.ch1
Mochly‐Rosen, D., & Grimes, K. (2013) · SpringerBriefs in pharmaceutical science & drug development · doi:10.1007/978-3-319-02201-7_3
Khatry, D. (2013) · Journal of Medical Statistics and Informatics · doi:10.7243/2053-7662-1-4
Process engineering of liver cells for drug testing applications
Tostões, R. M. (2012) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Deyati, A., Younesi, E., Hofmann‐Apitius, M., & Novac, N. (2013)
Strategy of target validation from a novel risk factor of schizophrenia / bipolar disorder
Miyake, S., Tajinda, K., & Matsumoto, M. (2013) · Folia Pharmacologica Japonica · doi:10.1254/fpj.142.271
The role of neuroimaging biomarker in drug discovery for schizophrenia
Ozaki, S. (2012) · Folia Pharmacologica Japonica · doi:10.1254/fpj.140.107
A Continuum of Reproducible Research in Drug Development
Folkers, G., & Baier, S. (2016) · John Wiley & Sons, Inc. eBooks · doi:10.1002/9781118865064.ch14 · Cited by 1
Discovery and Development of Tafamidis for the Treatment of TTR Familial Amyloid Polyneuropathy
Labaudinière, R. F. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781782624202-00202
Computational phenotypic assessment of small molecules in drug discovery
Loging, W., & Freeman, T. B. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9780511989421.006
Dark Side of Molecular Techniques: How to Fix It ?Preprint
Bhardwaj, V. (2016) · Preprints.org · doi:10.20944/preprints201608.0016.v1
Multiobjective Optimization of Biological and Physical Properties in Drug Discovery
Gleeson, M. P., & Montanari, D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12315-7 · Cited by 1
Jeon, J., Hotaling, N. A., & Bharti, K. (2016) · Wiley eBooks · doi:10.1002/9781119135449.ch22
Dutt, N., & Vidal, E. (2016) · SSRN Electronic Journal · doi:10.2139/ssrn.2866537
Gill, R. K. (2015) · TSpace (University of Toronto) · Cited by 1
Flipping the odds of drug development success through human genomicsPreprint
Hingorani, A. D., Kuan, V., Finan, C., Krüger, F. A., Gaulton, A., Chopade, S., Sofat, R., MacAllister, R. J., Overington, J. P., Hemingway, H., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/170142
The Challenges of Implementing Multiarmed Early Phase Oncology Clinical Trials
Hong, D. S., & Barata, P. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812512-0.00005-1
How Quality Can Improve Reproducibility
Lanati, A. (2018) · Springer eBooks · doi:10.1007/978-3-319-76750-5_2
Yokoi, T., & Oda, S. (2017) · KAGAKU TO SEIBUTSU · doi:10.1271/kagakutoseibutsu.55.412
Future Needs in Issue Resolution of Problems That Arise in Drug Development
Pugsley, M. K., Abernathy, M. M., Whitney, T. M., Authier, S., Renger, J. J., & Curtis, M. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812206-8.00015-7
Biologic Markers in Clinical Trials and Clinical Care
Boyle, D. L., & Robinson, W. H. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-31696-5.00034-6
Bioinformatics Identification of Drug Gene Modules: Application to Clear Cell Carcinoma of the Ovary
Tchagang, A. (2018) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc.2018.8512230
Improving Clinical Trial Design in Gastrointestinal Oncology
Atasoy, A., & Mauer, M. E. L. (2019) · Springer eBooks · doi:10.1007/978-3-030-18890-0_28
Identifying Novel Targets by using Drug-binding Site Signature: A Case Study of Kinase InhibitorsPreprint
Naveed, H., Reglin, C., Schubert, T. E. O., Gao, X., Arold, S. T., & Maitland, M. L. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/860510
Pauli, C., Moch, H., & Rubin, M. A. (2017) · Der Pathologe
Pendentancy-Based Molecular Descriptors for QSAR/QSPR Studies
Khatri, N., Dureja, H., & Мадан, А. К. (2020) · Apple Academic Press eBooks · doi:10.1201/9780429022951-22
RNAi Screens: Triumphs and Tribulations
Seyhan, A. A., & Carini, C. (2014) · doi:10.1201/b16749-6
UNCERTAINTY AND POPULATION VARIABILITY
Peters, S. A. (2021) · Wiley eBooks · doi:10.1002/9781119497813.ch9
Numao, S., Etienne, G., Malojcic, G., Schmidt, E. K., & Dumelin, C. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00078-5
Yamaguchi, S., & Narukawa, M. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2063
Trottet, L., & Maïbach, H. I. (2017) · Springer eBooks · doi:10.1007/978-3-319-59504-7_1
Martić-Kehl, M. I., Festing, M. F. W., Alvarez, C. E., & Schubiger, P. A. (2016) · Methods and principles in medicinal chemistry · doi:10.1002/9783527695881.ch1
Asia — The Future in Generics & Biosimilars (Vol. 17, No. 5, Full Issue)
(2013) · Asia-Pacific Biotech News · doi:10.1142/s0219030313001043
Gould, A. L. (2014) · Wiley eBooks · doi:10.1002/9781118763070.ch1
Drug Pharmacokinetics and Toxicokinetics
El‐Kattan, A. F. (2017) · Wiley eBooks · doi:10.1002/9781118916926.ch1
Neuroimaging in Psychiatric Drug Development and Radioligand Development for New Targets
Takano, A., Halldin, C., & Farde, L. (2020) · Springer eBooks · doi:10.1007/978-3-030-57231-0_1
(2013) · Asia-Pacific Biotech News · doi:10.1142/s0219030313000359
(2019) · Elsevier eBooks · doi:10.1016/b978-0-12-817443-2.00025-2
Kenakin, T. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99289-3.00006-3
Interpreting and Implementing Evidence for Quality Research
Cahan, E. M., & Shea, K. G. (2022) · Springer eBooks · doi:10.1007/978-3-031-07105-8_13
Voitsitskyi, T., Stratiichuk, R., Koleiev, I., Popryho, L., Ostrovsky, Z., Henitsoi, P., Khropachev, I., Vozniak, V., Zhytar, R., Nechepurenko, D., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.24.517815
How to Mitigate Unintentional Misconduct with Samples and Data in Biorepositories
Simeon‐Dubach, D., & Kozlakidis, Z. (2022) · Springer eBooks · doi:10.1007/978-3-030-99680-2_46
Animal Models of Lymphoid Malignancies
Mishra, A. (2023) · Wiley eBooks · doi:10.1002/9781119819950.ch4
Mochel, J. P., & Allenspach, K. (2023) · Preprints.org · doi:10.20944/preprints202305.1827.v1
Useful Computational Chemistry Tools for Medicinal Chemistry
Green, D. V. S., & Edge, C. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781788018982-00094
Ensemble learning methods for drug-induced liver injury identification
Chen, P., Wang, B., Zhang, J., Wang, Y., & Xiao, Q. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-824386-2.00011-0
Altunel, E., Roghani, R. S., Chen, K., Kim, S. Y., McCall, S. J., Ware, K. E., Shen, X., Somarelli, J. A., & Hsu, D. S. (2020) · Figshare · doi:10.6084/m9.figshare.12561017
Kenakin, T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14124-9.00001-x
Humanized mouse models in immuno-oncology
Li, S., & Wang, Q. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00024-2
Umeyor, C. E., Nayak, A., Uronnachi, E., Shah, P., Okeke, T., Okezie, U. M., Bairagi, G., & Patravale, V. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23841-3.00020-0
Metadata
- Authors
- Arrowsmith, J.
- Affiliations
- Thomson Reuters (United Kingdom) (GB)
- Corresponding author
- Arrowsmith, John
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-04-29
- Volume
- 10
- Issue
- 5
- Pages
- 328-329
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2065540447
- Cited by
- 622
- References
- 0
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 22 · 2023: 14 · 2022: 21 · 2021: 25 · 2020: 36 · 2019: 44 · 2018: 37 · 2017: 54 · 2016: 64 · 2015: 66 · 2014: 66 · 2013: 88 · 2012: 41
- Type
- other
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Science, Research, and Medicine
- Keywords
- drug development failure, clinical trial attrition, drug repurposing, translational research
- MeSH terms
- Drug Industry, Pharmaceutical Preparations, Humans, Drug Design, Treatment Failure, Clinical Trials, Phase II as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.